Minerva Neurosciences Inc Common Stock (NERV)

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

7

Website

www.minervaneurosciences.com

Fundamentals

1-day range

$4.3$4.79

Market cap

$184.96M

P/E (trailing)

—

P/E (forward)

-10.90

EPS (trailing)

$-36.12

Dividend yield

—

Beta

-0.11

Avg. volume

227.5K

Forecasts

3 analyst ratings

Minerva Neurosciences Inc Common Stock Competitors

Chosen by industry and closest market cap.

• NERV

  Minerva Neurosciences Inc Common Stock

  $4.85

  ▼ 5.56%
  Market cap $184.96MP/E —
  $1.93$12.46
• NBP

  NovaBridge Biosciences American Depositary Shares

  $1.85

  ▼ 2.38%
  Market cap $185.76MP/E —
  $1.46$6.79
• IMUX

  Immunic Inc. Common Stock

  $15.4

  ▼ 5.52%
  Market cap $192.06MP/E —
  $5.06$17.43
• EVO

  Evotec SE American Depositary Shares

  $1.91

  ▼ 2.80%
  Market cap $172.06MP/E —
  $3.18$7.3
• GLSI

  Greenwich LifeSciences Inc. Common Stock

  $15.67

  ▼ 16.34%
  Market cap $198.74MP/E —
  $7.78$34.1
• ARCT

  Arcturus Therapeutics Holdings Inc. Common Stock

  $15.19

  ▼ 6.06%
  Market cap $170.54MP/E —
  $5.5$24.17
• TNXP

  Tonix Pharmaceuticals Holding Corp. Common Stock

  $13.59

  ▲ 0.18%
  Market cap $170.01MP/E —
  $9.4$34.04

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
  Benzinga · 8/14/2026
• Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10
  Benzinga · 8/14/2026
• Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate
  Benzinga · 8/7/2026

• Kaul Inderjit · August 3, 2026 · Grant

  12.1K
• Kaul Inderjit · June 3, 2026 · Grant

  50.0K
• Kupfer David · June 3, 2026 · Grant

  50.0K
• Laghrissi-Thode Fouzia · June 3, 2026 · Grant

  50.0K
• Remy Luthringer · June 3, 2026 · Grant

  1.69M
• Frederick W. Ahlholm · June 3, 2026 · Grant

  680.0K
• HASLER HANS PETER · June 3, 2026 · Grant

  50.0K
• VAN HEEK G JAN · June 3, 2026 · Grant

  50.0K
• O'Connor James Joseph · April 21, 2026 · Grant

  350.8K
• Kaul Inderjit · March 31, 2026 · Grant

  12.2K

Institutional Ownership

March 31, 2026

Total shares held

38.01M

Total value held

$229.01M

Institutional holders

42